Objective: The aim of this study was to evaluate the effectiveness of postoperative levonorgestrel-releasing intrauterine system (LNG-IUS) insertion after gonadotropin-releasing hormone agonist (GnRH-a) treatment for preventing endometriotic cyst recurrence. Study Design: The LNG-IUS was applied to 28 women who had undergone surgery for endometriosis followed by 6 cycles of GnRH-a treatment. Clinical characteristics, endometriosis recurrence, and adverse effects were analyzed. Student t test was performed for analysis. Results: Before surgery, 20 (71.4%) patients had dysmenorrhea, and the mean pain score (visual analog scale [VAS]) was 4.26. The numbers of women diagnosed with stage III endometriosis and stage IV endometriosis were 15 (53.6%) and 13 (46.4%), respectively, according to the revised American Fertility Society scoring system. The mean cancer antigen 125 levels and VAS scores were significantly lower after treatment than before treatment (11.61 vs 75.66 U/mL, P < .0001 and 0.50 vs 4.26 U/mL, P < .0001, respectively). Of the 28 patients, 13 (46.4%) simultaneously had adenomyosis, and 2 (7.1%) underwent LNG-IUS removal because of unresolved vaginal bleeding and dysmenorrhea. Recurrence was noted in 2 (7.1%) women. Conclusion: Postoperative LNG-IUS insertion after GnRH-a treatment is an effective approach for preventing endometriotic cyst recurrence, especially in women who do not desire to conceive.
Introduction
Endometriosis is a common gynecological disorder that is responsible for dysmenorrhea, dyspareunia, chronic pelvic pain, and infertility, and affects 10% to 20% of women of reproductive age worldwide. 1, 2 Surgery is usually considered as the treatment of choice for endometriosis 3 ; however, the recurrence rate following surgery remains high. For instance, a meta-analysis of 23 studies estimated recurrence rates of 21.5% at 2 years and 40% to 50% at 5 years. 4 Endometriosis progresses in an estrogen-dependent fashion, and it is recommended to use postoperative hormonal therapy, including gonadotropin-releasing hormone agonist (GnRH-a), progestin, and combined oral contraceptives (OCs), to induce pseudomenopausal or pseudopregnancy states and prevent recurrence. 5, 6 Gonadotropin-releasing hormone agonist is frequently used in women with endometriosis because it can suppress possible residual endometriotic lesions through its estrogen-lowering effects. However, its efficacy for preventing recurrence when used alone is still controversial, and its use as a long-term treatment is limited by significant adverse effects. 7, 8 Previous studies mentioned that the endometrioma recurrence rate was significantly lower with GnRH-a followed by long-term OC use than with GnRH-a alone. 9, 10 Consequently, no single postoperative medical therapy has been shown to be superior in reducing the recurrence of endometrioma, while combinations of treatment modalities have been shown to be effective.
Oral contraceptives have generally been easily chosen for preventing recurrence of endometriosis. Many patients tend to consider oral medications more approachable than insertion of an implant inside the body. For the prevention of endometriosis recurrence, long-term medication is important. However, many Koreans are reluctant to take hormonal pills for a long duration, and they tend to show deteriorating compliance to treatment because of cultural bias against OCs. 11, 12 Therefore, there is a need for another long-term hormonal treatment that can be maintained with better patient compliance.
Recently, the levonorgestrel-releasing intrauterine system (LNG-IUS) was studied to determine whether its efficacy is comparable to that of other hormonal therapies for the treatment of several aspects of endometriosis. The 2014 Cochrane review 13 concluded that the LNG-IUS was beneficial for women with pain and endometriosis. Morelli et al observed that OC use appeared more effective than LNG-IUS for reducing pain and the recurrence rate, without significance, and that the LNG-IUS showed a significantly higher patient satisfaction.
14 When compared with OCs, the LNG-IUS has some advantages, such as longer duration of action (4-5 years) and fewer systemic hormonal adverse reactions. Our previous retrospective study indicated that postoperative LNG-IUS use after 3 GnRH-a cycles was as effective as OC use after GnRH-a treatment for preventing endometriosis recurrence. 15 To date, no prospective study has evaluated the efficacy of postoperative GnRH-a and the LNG-IUS for the prevention of endometriosis recurrence. The present study aimed to assess the effectiveness of postoperative LNG-IUS insertion after 6 cycles of GnRH-a for preventing endometriotic cyst recurrence. The primary outcome was ovarian endometrioma recurrence, and the secondary outcome was the recurrence of symptoms such as dysmenorrhea and menorrhagia. To our knowledge, this is the first such prospective study in the literature.
Materials and Methods
This prospective study was conducted in accordance with the ethical standards of the Helsinki Declaration and was approved by the institutional review board of Yonsei University Health System, Severance Hospital. This study considered 32 patients who underwent laparoscopic surgery for endometriosis between March 2010 and July 2016, for inclusion. All surgeries were conducted by a single surgeon. The inclusion criteria were as follows: (1) laparoscopically diagnosed endometriosis with pathological confirmation, (2) premenopause without a desire to conceive, (3) absence of residual ovarian lesions on transvaginal ultrasonography before LNG-IUS insertion, and (4) consent for 6 months of GnRH-a treatment and LNG-IUS insertion. The exclusion criteria were hysterectomy during surgery, refusal for LNG-IUS insertion, history of malignancy or cardiovascular disease, and absence of follow-up clinic visits after LNG-IUS insertion.
The patients' preoperative gynecological history, pain scores (visual analog scale [VAS]), sonographic findings, cancer antigen 125 (CA 125) levels, total revised American Fertility Society scores (rAFS), and stages were evaluated. After surgery, patients received 6 cycles of GnRH-a (leuprorelin or triptorelin acetate 3.75 mg subcutaneous injection every 4 weeks), and sonographic evaluation for endometrioma recurrence was performed after 4 weeks from the last GnRH-a injection. The LNG-IUS (Mirena, Bayer Ag, Turku, Finland) was inserted after confirming that there was no recurrence according to sonographic results. Endometrioma recurrence was diagnosed when a round mass having a thick wall, minimum diameter of 2 cm, regular margins, and homogenous low echogenic fluid content with scattered internal echoes, without papillary projection, was noted on ultrasonography. 16 Patients were also evaluated to determine whether they simultaneously had adenomyosis. The sonographic criteria for adenomyosis were as follows: (1) abnormal heterogeneous myometrium with areas of increased or decreased echogenicity, (2) hypoechoic striations ("venetian blind") in the myometrium, (3) hyperechogenic foci representing endometrial tissue in the myometrium, (4) diffuse hypervascularity throughout the lesion. 17 The patients were followed up every 6 months for the first year after LNG-IUS insertion, and once every year from the second year, unless there were specific symptoms that needed extra treatment. Patient symptoms, CA 125 levels, and sonographic changes were assessed during follow-up clinic visits.
Data are expressed as mean + standard error of the mean, and Student t test was used for the comparison of continuous variables. A P value < .05 was considered statistically significant.
Results
A total of 32 patients who underwent laparoscopic surgery for endometriosis were enrolled in this study. Four patients were excluded because of follow-up loss after LNG-IUS insertion. Therefore, 28 patients were included for evaluation, and 85.7% of these patients had clinic follow-up for more than a year after LNG-IUS insertion. The mean duration of follow-up was 36 months. The patient characteristics before treatment are described in Table 1 .
Overall, 25 (89.3%) patients received 6 cycles of GnRH-a before LNG-IUS insertion. The remaining 3 (10.7%) patients received a less number of GnRH-a cycles because of difficulty in enduring menopausal symptoms. Of the 28 patients, 8 (28.6%) experienced menopausal symptoms as GnRH-a adverse effects, including vasomotor symptoms, pain, and insomnia. The number of women diagnosed with stage III endometriosis was 15 (53.6%) and stage IV endometriosis was 13 (46.4%), according to the rAFS scoring system. After surgery and LNG-IUS insertion, several variables were evaluated and compared with the preoperative results. The mean CA 125 levels and VAS scores were significantly lower after treatment than before treatment (11.61 vs 75.66 U/mL, P < .0001 and 0.50 vs 4.26 U/mL, P < .0001, respectively). Only 1 patient continued to have severe dysmenorrhea (VAS score 7) and prolonged menstruation, and she used additional OCs. Another patient had increased uterine bleeding and needed uterine artery embolization. These patients were suspected of having adenomyosis from the preoperative gynecological sonography assessments, and they eventually had their LNG-IUS removed.
Of the 28 patients, 8 (28.6%) had LNG-IUS-associated adverse effects. Seven patients had vaginal spotting and 1 patient experienced weight gain of 6 to 7 kg. The vaginal spotting resolved either spontaneously or with short-term OC treatment, and all patients with temporary adverse effects continued using the LNG-IUS. There was no incidental expulsion of the LNG-IUS.
A total of 2 (6.9%) patients had recurrent endometriomas and additionally needed dienogest. These patients had newly formed endometrioma on the ovary opposite to the one that had undergone surgery previously. One patient was in endometriosis stage III with rAFS 36, had VAS 4 dysmenorrhea before surgery, and the recurrence was found 2 years after LNG-IUS insertion. Another patient was in stage IV with rAFS 64, experienced severe dysmenorrhea (VAS 8), and had previous history of myomectomy and cesarean delivery. Her recurrence was first detected 7 months after LNG-IUS insertion. The patients did not experience any adverse effects of dienogest, and the recurrent endometriomas slightly decreased in size or remained the same.
Discussion
To our knowledge, this is the first prospective study with a single cohort of patients using both GnRH-a and the LNG-IUS for the medical treatment of endometriosis. The results indicated a significant effect for maintaining decreased CA 125 levels and VAS scores. Additionally, this approach showed high efficacy for preventing endometrioma recurrence.
Endometriosis recurrence is usually explained by the following 2 possible pathogeneses: regrowth of residual lesions after surgery and de novo lesion formation. 18 Vignali et al. 19 mentioned that during the second surgery for endometriosis, deep endometriosis recurrence was often noted in the same area of the pelvis that was initially operated upon. Recurrence can also result from a satellite lesion in areas with multiple endometriotic foci that were difficult to eliminate during conservative surgery. 20 Another explanation is de novo endometriosis formation through retrograde menstruation or ovulation of the remnant ovaries. Bulletti et al. reported excellent prevention of endometriosis recurrence after laparoscopic surgery combined with endometrial ablation 21 ; however, another study reported endometriosis recurrence after hysterectomy. 22 Interestingly, other studies have also stated that ovulation may cause endometriosis after observing the development of ovarian endometrioma derived from a growing follicle or the corpus luteum. 23 Conclusively, recurrence may result from residual endometriotic lesions, retrograde menstruation, growing follicles, or the corpus luteum, and all of these are induced by hormonally active ovaries. Our approach tried to block all of these pathogeneses. Gonadotropin-releasing hormone agonist was used to transiently halt the hormonal signal to the ovaries associated with the induction of the menstrual cycle, and the LNG-IUS was applied to maintain a thin endometrium and prevent retrograde menstruation. Theoretically, this was the perfect longterm medical treatment to prevent endometriosis recurrence.
Interestingly, there were 2 patients with recurrent endometrioma on the opposite ovary even after 6 months of GnRH-a treatment and LNG-IUS insertion. We speculate that these recurrences occurred from the microsatellite endometriotic implants that were not visible during the operation. We noticed that the patient who had more severe preoperative symptoms, higher endometriosis stage, and history of cesarean delivery, which might have increased the odds of endometrial cells contaminating the intra-abdominal cavity, had shorter amount of time until recurrence. It might be possible that patients with prior history of surgery which exposes the endometrium (such as cesarean delivery) and severe dysmenorrhea may have higher risk of endometrioma recurrence even with GnRH-a and LNG-IUS treatment. However, further studies with larger number of study participants and longer follow-up duration will be needed to confirm this hypothesis.
There were few setbacks that made this GnRH-a with LNG-IUS treatment method unsuitable for every endometriosis patient. First, GnRH-a for 6 cycles may be a burden for some patients. We used 6 cycles of GnRH-a to maximally take advantage of its effect in stopping ovulatory functions of the ovaries and minimize the actions of remnant endometriosis foci. However, induction of a transient menopausal status in premenopausal women has resulted in postmenopausal syndrome symptoms, such as vasomotor symptoms, pain, and insomnia, in some patients. To continue with GnRH-a therapy, these patients needed additional OC or hormonal replacement therapy for alleviating postmenopausal symptoms. In this study, 28.6% of the patients had these symptoms and could be managed with additional medication, while 10.7% did not tolerate the full 6 cycles of GnRH-a and LNG-IUS insertion before reaching the goal. It is important to identify such patients and customize the treatment method according to the drug response experienced. Second, the treatment method presented in this study may not be suitable for younger patients (those in their 20s or teenagers). Endometriosis is also found in younger women who have not yet gotten married, given birth to a child, or had sexual intercourse. The LNG-IUS is usually preferred by parous women because of convenience and limited or no pain during insertion. For nulliparous young women, it may be difficult and sometimes culturally unacceptable to apply an intrauterine device. This study cohort only included women in their 30s or 40s who had a history of sexual intercourse, and majority of the women (86.2%) had parity of one or more. Additionally, the use of maximal doses of GnRH-a in younger patients should be avoided as it may cause bone loss, and hormonal add-back treatment might be necessary. 24 This approach can be very inefficient and not cost-effective, as OCs alone are known to be effective in preventing endometriosis recurrence. 6, 25 It would be advisable to apply the present treatment method to older premenopausal women with a history of sexual activity and those who do not desire to conceive.
Nonetheless, GnRH-a treatment followed by LNG-IUS insertion is an attractive treatment approach for several reasons. First, this approach may be suitable for patients who cannot keep up with daily medications. A single injection of GnRH-a per month and keeping the LNG-IUS inserted for 4 to 5 years avoids the troublesome daily intake of OCs. Previous studies have reported that it is important to keep using OCs for a long period to prevent recurrence, as the effect appears to disappear rapidly after discontinuation. 6, 25, 26 For patients who are not very compliant with treatment protocols or cannot visit clinics often, our approach may be appropriate.
Second, many LNG-IUS users can benefit from becoming amenorrheic or tremendously decreased amount of menstruation. Endometriosis is often accompanied by adenomyosis, and a previous study reported that pelvic pain may be correlated with the presence of adenomyosis. 27 In the cohort of the present study, 46.4% of patients were suspected to have adenomyosis simultaneously, and almost all of these patients benefited from less vaginal bleeding and remarkably decreased dysmenorrhea. Only 1 exceptional case failed to achieve the therapeutic effect of the LNG-IUS and needed uterine artery embolization. Overall, the LNG-IUS was very effective in controlling the amount of menstruation.
Third, GnRH-a use plus LNG-IUS insertion improved patient compliance, and a low number of women removed their LNG-IUS. Previous studies described the following adverse effects of the LNG-IUS: (1) prolonged intermenstrual bleeding/spotting, (2) weight gain, (3) simple ovarian cyst development, (4) backache, (5) lower abdominal pain, (6) breast tenderness, and (7) skin problems, such as acne. 28, 29 Kriplani et al. 29 reported prolonged intermenstrual spotting in as many as 71.4% of the participants. However, in this study, only 25% of the patients experienced vaginal spotting, which spontaneously resolved. Additionally, only 1 patient experienced weight gain, and there were no other reported adverse effects. With GnRH-a use, the initial problematic hormonal effects of the LNG-IUS appear to decrease; however, further studies will be needed to confirm this finding.
In conclusion, our approach involving 6 cycles of GnRH-a and subsequent LNG-IUS insertion was effective in preventing endometriosis recurrence. The symptoms of endometriosis, such as dysmenorrhea, successfully resolved, and patients were able to benefit from the effective control of menorrhagia. Future studies with larger cohorts and longer follow-up evaluations will be needed to further confirm our findings.
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